

GUIDELINE

Open Access



# Transthoracic Echocardiographic Assessment of the Heart in Pregnancy—a position statement on behalf of the British Society of Echocardiography and the United Kingdom Maternal Cardiology Society

Stephanie L. Curtis<sup>1\*</sup>, Mark Belham<sup>2</sup>, Sadie Bennett<sup>3</sup>, Rachael James<sup>4,5</sup>, Allan Harkness<sup>6</sup>, Wendy Gamlin<sup>7</sup>, Baskaran Thilaganathan<sup>8</sup>, Veronica Giorgione<sup>8</sup>, Hannah Douglas<sup>9</sup>, Aisling Carroll<sup>10</sup>, Jamie Kitt<sup>11</sup>, Claire Colebourn<sup>11</sup>, Isabel Ribeiro<sup>1</sup>, Sarah Fairbairn<sup>1</sup>, Daniel X. Augustine<sup>12,13</sup>, Shaun Robinson<sup>14</sup> and Sara A. Thorne<sup>15</sup>

## Abstract

Pregnancy is a dynamic process associated with profound hormonally mediated haemodynamic changes which result in structural and functional adaptations in the cardiovascular system. An understanding of the myocardial adaptations is important for echocardiographers and clinicians undertaking or interpreting echocardiograms on pregnant and post-partum women. This guideline, on behalf of the British Society of Echocardiography and United Kingdom Maternal Cardiology Society, reviews the expected echocardiographic findings in normal pregnancy and in different cardiac disease states, as well as echocardiographic signs of decompensation. It aims to lay out a structure for echocardiographic scanning and surveillance during and after pregnancy as well as suggesting practical advice on scanning pregnant women.

**Keywords** Pregnancy, Echocardiography, Obstetric

## \*Correspondence:

Stephanie L. Curtis

Stephanie.Curtis@uhbw.nhs.uk

<sup>1</sup> University Hospitals Bristol and Weston NHS Trust, Bristol Heart Institute, Marlborough Street, Bristol BS2 8HW, UK

<sup>2</sup> Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

<sup>3</sup> University Hospitals of North Midlands, Stoke-On-Trent, UK

<sup>4</sup> University Hospitals Sussex NHS FT, Brighton, UK

<sup>5</sup> United Kingdom's Maternal Cardiology Society, London, UK

<sup>6</sup> East Suffolk and North Essex NHS Foundation Trust, Essex, UK

<sup>7</sup> North West Heart Centre, Wythenshawe Hospital, Manchester, UK

<sup>8</sup> St George's University Hospitals NHS Trust, London, UK

<sup>9</sup> Guy's and St Thomas' NHS Trust, London, UK

<sup>10</sup> University of Southampton NHS Trust, London, UK

<sup>11</sup> Oxford University Hospitals NHS Foundation Trust, Oxford, UK

<sup>12</sup> Royal United Hospitals Bath NHS Foundation Trust, Bath, UK

<sup>13</sup> Department for Health, University of Bath, Bath, UK

<sup>14</sup> Imperial College Healthcare NHS Trust, London, UK

<sup>15</sup> University Health Network Toronto, Toronto General Hospital & Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Introduction**

Heart disease is the commonest cause of maternal death in the UK and other high income countries [1], and lessons can be learned that could have altered the outcome in more than half of cases. Most deaths have occurred in women who were not previously known to have had heart disease, and echocardiography is often the key tool in making a diagnosis in the acute setting. It is also crucial for assessing and risk stratifying women with known heart disease prior to and during pregnancy, providing a comprehensive assessment of cardiac anatomy, function and haemodynamics.

Pregnancy is a dynamic state that is associated with major hormonally mediated changes that result in numerous physiological adaptations. These comprise significant physiological and hemodynamic changes within the cardiovascular system, including structural and functional adaptations of the myocardium [2, 3]. These changes serve to meet the increased metabolic demands demanded of the mother, whilst supporting the growth and development of the fetus. The inability of the myocardium to adapt sufficiently to these changes during pregnancy and the puerperium may result in poor maternal and / or fetal outcomes [3]. It is important that echocardiographers and clinicians have an understanding of the normal and abnormal cardiac structural and functional adaptations seen both during pregnancy and the post-partum period.

This guideline, on behalf of the British Society of Echocardiography (BSE) and the United Kingdom Maternal Cardiology Society (UKMCS), aims to provide an overview of the following areas.

1. Normal echo findings during pregnancy.
  - Structural changes in normal pregnancy.
  - Functional changes during normal pregnancy.
2. Echocardiography of pregnancy induced heart disease.
  - Peripartum cardiomyopathy.
  - Pulmonary embolism.
  - Aortic dissection.
  - Acute coronary syndrome.
  - Hypertensive disorders of pregnancy.
3. Echocardiography in pregnancy in pre-existing heart disease
  - Valvular heart disease.
  - Cardiomyopathies.
  - Pulmonary arterial hypertension.
  - Congenital heart disease.
4. Echocardiography triage and surveillance during and after pregnancy.
5. Practical advice on scanning pregnant women.

Levels of evidence and strengths of recommendation are shown in Tables 1 and 2. These underscore the reality that a guideline does not take the place of high quality clinical surveillance and decision-making by the health-care professionals involved in the care of the pregnant woman. The Class of Recommendation (Table 1) indicates the strength of the recommendation, incorporating the estimated benefit in proportion to risk. The Level of Evidence (Table 2) rates the quality of the scientific evidence supporting the recommendation, based on type,

**Table 1** Classes of recommendation

Classes of recommendations	Definition	Suggested wording to use
Class I	Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective	Is recommended/is indicated
Class II	Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure	
• Class IIa	Weight of evidence/opinion is in favour of usefulness/efficacy	Should be considered
• Class IIb	Usefulness/efficacy is less well established by evidence/opinion	May be considered
Class III	Evidence or general agreement that given treatment or procedure is not useful/effective and in some cases may be harmful	Is not recommended

**Table 2** Levels of evidence

Level of evidence A	Data derived from multiple randomised clinical trials or meta-analyses
Level of evidence B	Data derived from a single randomised clinical trial or large non-randomised studies
Level of evidence C	Consensus of opinion of the experts and/or small studies, retrospective studies, registries

quantity, and consistency of data from clinical trials and other sources.

It should be noted that, whilst most studies should be done using the BSE Transthoracic Echocardiography (TTE) Minimum Dataset, on occasion a BSE Level 1 scan may be most appropriate, for example in acute admissions in the emergency department. Some frequently repeated studies in the cardiac antenatal clinic however will be focussed studies guided by senior clinicians, as a minimum dataset TTE will previously have been acquired. If not, a full study needs to be performed.

## Normal echo findings during pregnancy

### Structural changes in normal pregnancy

The most notable changes seen during pregnancy are an increase in blood volume, accommodated by an increase in heart rate and stroke volume, and consequently, cardiac output. These changes typically commence within the first trimester with an increase in cardiac output of up to 50% compared to non-pregnant levels [4]. The sustained increase in blood volume leads to balanced, subtle dilatation of all four cardiac chambers [5–7]. This begins at around 12 weeks of gestation and progresses throughout pregnancy [8]. However, it is important to note that during a normal pregnancy the extent of the dilatation is small with chamber sizes remaining within normal limits. Moreover, these changes recover within three to six months of delivery [6, 7, 9].

The increase in left ventricular dimensions results in eccentric symmetrical hypertrophy. There is a 5–10% overall increase in left ventricular mass [10] and wall thickness of 25–30% above pre-pregnancy levels, all staying within normal values [3]. LV sphericity progressively increases, occurring early, and recovering by three to six months post-partum [6, 9]. Hypertrabeculation has also been shown to develop, more commonly in Afro-Caribbean than Caucasian women, and this is thought to be due to increased preload, analogous to the changes that occur in the athlete's heart [11]. These changes again resolve post-partum in the majority of women, though full resolution may take up to two years [11].

Asymptomatic small pericardial effusions of no haemodynamic consequence occur in approximately 40% of pregnancies. These are more common in the third trimester and if there has been a weight gain of >12 kg in the pregnancy. These typically resolve by six weeks post-partum and do not need further review [12] (IIC).

### Functional changes during normal pregnancy

There is no significant change in left ventricular ejection fraction throughout pregnancy and post-partum [6, 9, 13–18]. However, a subtle decline to low normal [19] has

been observed from the second trimester, persisting into the early post-partum period [5, 7].

Global longitudinal strain (GLS) steadily declines to the lower end of the normal range [5, 6, 14, 20] in the second trimester, after which it remains stable until term. An increase in GLS above normal is commonly seen post-partum [5, 6]. Data on circumferential and radial strain are sparse [6]. Left ventricular torsion increases during pregnancy, from the second trimester onwards until term, after which it returns to normal [14, 21].

Left ventricular diastolic function is more difficult to interpret during pregnancy as trans-mitral inflow is strongly influenced by loading conditions [8, 22, 23]. The increase in preload, coupled with a decrease in afterload in early pregnancy, results in an increase in mitral E wave velocity, a lowering of A wave velocity and corresponding increase in E/A ratio. These parameters return to normal within one year post-partum [18, 23]. E/e', as a relatively load independent measure, remains unchanged throughout pregnancy [2, 5, 23–25]. The true incidence of diastolic dysfunction during pregnancy is unclear as many studies have used outdated methodologies [22] or non-standard definitions.

Data on right ventricular function in pregnancy are limited to a few small studies. GLS and fractional area change have been shown to decline to low normal as pregnancy progresses [26] but tissue Doppler imaging (TDI) peak S' velocity has been shown not to change; all return to normal postpartum [26].

An illustration of normal intervals found in a study of 559 women is shown in Table 3. However, it should be noted that, in general, the subtle changes in parameters of ventricular function seen during pregnancy remain within normal limits. Echocardiographers should therefore still use the BSE guidelines to assess whether a chamber is enlarged.

Findings that should raise an alert and prompt clinical review can be found in Table 4. Care of pregnant is best jointly managed by a team of specialist cardiologists, obstetricians and obstetric anesthetists, known as the pregnancy heart team.

## Echocardiography of pregnancy induced heart disease

### Peripartum cardiomyopathy

Peripartum cardiomyopathy (PPCM) is defined as an idiopathic cardiomyopathy presenting with heart failure secondary to left ventricular systolic dysfunction towards the end of pregnancy or within the first five months following delivery, where no other cause of heart failure is found [27]. A reduction in left ventricular ejection fraction (usually <45%) with or without left

**Table 3** Typical changes in cardiac size (A) and function (B) of the left ventricle for 559 pregnant women by trimester adapted from [8]

	< 20 weeks Median	> 20 weeks Median
<b>A</b>		
LVEDd (cm)	4.5	4.6
LVESd (cm)	3.1	3.1
LVEDvol (mL)	88	88
LVESvol (mL)	33	34
PWTd (cm)	0.8	0.8
IVSd (cm)	0.7	0.7
LA volume (mL)	54	54
LVMI (g/m <sup>2</sup> )	61	63
<b>B</b>		
LVEF (%)	61	61

Based on 137 women (< 20 weeks) and 274 women (20+ weeks) and shown as median with interquartile range

*LVEDd* left ventricular end diastolic dimension, *LVESd* left ventricular end systolic dimension, *LVEDvol* left ventricular end diastolic volume, *LVESvol* left ventricular end systolic volume, *PWTd* posterior wall thickness in diastole, *IVSd* interventricular septal wall thickness in diastole, *LVEF* left ventricular ejection fraction, *LA* left atrium, *LVMI* left ventricular mass index

ventricular dilatation is required to establish a diagnosis. Around two thirds of women with PPCM develop it postpartum [27].

PPCM can be difficult to distinguish from pre-existing dilated cardiomyopathy (DCM) presenting de novo in pregnancy, although DCM may present at an earlier gestation. Echocardiographic assessment of PPCM and DCM is the same.

Echocardiography can help predict prognosis and / or recovery in PPCM [28]; a left ventricular ejection fraction of  $\leq 30\%$  at presentation confers a poorer prognosis and reduced likelihood of recovery [28], as does a global longitudinal strain of  $> -10.6\%$ , global circumferential strain of  $< 10.1\%$  [29], and left ventricular end diastolic diameter (LVEDd) of  $\geq 6$  cm [28]. Impaired right ventricular (RV) function co-exists in a quarter to a third of women with PPCM [30–32]. Again, echocardiographic measurements can be indicative of a poorer prognosis: TAPSE (tricuspid annular plane systolic excursion)  $< 16$  mm, TDI peak *S'* velocity of  $< 10$  cm/s [32], fractional area change  $< 36\%$ , and right ventricular end systolic area  $> 13$  cm<sup>2</sup> [33].

Echocardiography is also important in the assessment of left ventricular thrombus, which may complicate significant left ventricular impairment due to the hypercoagulable state of pregnancy [34].

There are no safety data for echo contrast agents in pregnancy and they should therefore generally be avoided unless the maternal benefit is considered to

outweigh the risk. This decision can be made by a senior physician from the pregnancy heart team.

### Pulmonary embolism

Pulmonary embolism (PE) is the most common “direct” (i.e. not pre-existing but relating to pregnancy) cause of maternal death in the UK [35]. Acute PE may lead to characteristic changes on echo, including reduced pulmonary acceleration time, reduced longitudinal motion of the free wall compared to a relatively hyperdynamic RV apex, signs of RV pressure overload, such as systolic septal flattening in the PSAX view, and thrombus in the right heart. While echocardiography is not the primary imaging modality to diagnose or exclude PE, it may point to alternative diagnoses and is of value in risk stratifying a proven PE [36].

### Aortic dissection

Whilst aortic dissection is uncommon during pregnancy, it accounts for 11% of maternal cardiac deaths in the UK [1], mostly occurring in the third trimester or early postpartum. Pregnancy increases the risk of dissection due to the hormonal and haemodynamic effects on the aortic wall [37, 38] and most affected women do not have a prior diagnosis of aortopathy [1]. It is often the dissection that leads to the underlying diagnosis, e.g. as Marfan, Loeys-Dietz and Turner syndromes [1, 38].

Patients with aortopathy are considered to be at highest risk if the aorta is  $> 45$  mm in hereditary aortopathies,  $> 50$  mm in bicuspid aortic valve associated aortopathy and  $> 25$  mm/m<sup>2</sup> in Turner syndrome. Identifying progressive dilatation in patients with known aortopathy is particularly important and these women should have regular echocardiographic surveillance. Images should be carefully compared with previous studies [39]. Recommended surveillance intervals are shown in Table 6.

Patients with a repaired or replaced aortic root remain at risk of more distal dilatation or dissection. Thus, echocardiography should include suprasternal and subcostal views to ensure that as many parts of the aorta are imaged as possible. Imaging with non-contrast magnetic resonance imaging to assess the entire aorta is safe during pregnancy and does not require the use of gadolinium contrast.

Any progression of aortic dilatation in a pregnant patient with known aortopathy should raise an alert and prompt clinical review [40].

### Acute coronary syndrome

Acute coronary syndromes in pregnancy may be due to atherosclerosis, pregnancy-related spontaneous coronary artery dissection or acute intra-coronary thrombosis

**Table 4** Changes on echocardiography in pregnancy that should raise an alert and prompt clinical review [27, 40]

Condition		Level of evidence and strength of recommendation
General recommendations		
General	<ul style="list-style-type: none"> <li>• Large one-off, or stepped changes in parameters, even if they remain in the normal range</li> </ul>	IC
	<ul style="list-style-type: none"> <li>• Measurements that fall outside normal values</li> </ul>	IC
Arrhythmia	<ul style="list-style-type: none"> <li>• Any abnormal rhythm, e.g. loss of sinus rhythm, frequent premature ventricular complexes</li> </ul>	IC
Aortopathy	<ul style="list-style-type: none"> <li>• Any progression of aortic dilatation</li> </ul>	IC
Valvular heart disease		
Aortic stenosis	<ul style="list-style-type: none"> <li>• Any decrease in LVEF, especially if accompanied by fall in transvalvar velocity</li> <li>• Any increase in LV systolic or diastolic dimensions</li> <li>• Tachycardia on echo (&gt; 100 beats per minute)</li> </ul>	IC IIC IC
Mitral stenosis	<ul style="list-style-type: none"> <li>• Any new diagnosis of mitral stenosis</li> <li>• Progression of severity</li> <li>• New onset atrial fibrillation</li> <li>• Left atrial spontaneous contrast or suspicion of thrombus</li> <li>• Any deterioration in RV function, increase in PA pressure or increase in RV dimensions</li> </ul>	IC IC IC IC IIC
Pulmonary stenosis	<ul style="list-style-type: none"> <li>• Deterioration in RV function</li> <li>• Increasing severity of tricuspid regurgitation</li> </ul>	IC IIC
Mitral regurgitation	<ul style="list-style-type: none"> <li>• Deterioration in LV function</li> <li>• Increase in LV systolic or diastolic dimensions</li> <li>• Increase in severity of mitral regurgitation</li> </ul>	IC IC IC
Aortic regurgitation	<ul style="list-style-type: none"> <li>• Deterioration in LV function</li> <li>• Increase in LV systolic or diastolic dimensions</li> <li>• Increase in severity of aortic regurgitation</li> </ul>	IC IC IC
Pulmonary regurgitation	<ul style="list-style-type: none"> <li>• Progressive increase in RV dimensions</li> <li>• Reduction in RV systolic function</li> <li>• Increasing severity of tricuspid regurgitation</li> </ul>	IIC IC IIC
Tricuspid regurgitation	<ul style="list-style-type: none"> <li>• Progressive increase in RV dimensions</li> <li>• Reduction in RV systolic function</li> <li>• Increasing severity of tricuspid regurgitation</li> </ul>	IIC IC IIC
Prosthetic valves	<ul style="list-style-type: none"> <li>• Any suspicion of mechanical valve dysfunction suggesting possible valve thrombosis</li> <li>• Other imaging modalities (fluoroscopy and/or TOE, rarely CT<sup>3</sup>) should be considered</li> </ul>	IC IIC
Cardiomyopathy		
PPCM	<ul style="list-style-type: none"> <li>• New LV dysfunction</li> <li>• Serial reduction in LV function</li> <li>• Serial increase in LV dimensions</li> <li>• Evidence of abnormalities associated with poor prognosis including: <ul style="list-style-type: none"> <li>• LVEF <math>\leq</math> 30%</li> <li>• LVEDd <math>\geq</math> 6 cm</li> </ul> </li> <li>• RV dilatation and dysfunction</li> </ul>	IC IC IC IC IC IIC
Dilated cardiomyopathy and previous PPCM	<ul style="list-style-type: none"> <li>• Serial reduction in LV function</li> <li>• Serial increase in LV dimensions</li> </ul>	IC IC
Hypertrophic cardiomyopathy	<ul style="list-style-type: none"> <li>• Newly detected LVOT obstruction</li> <li>• Deterioration in systolic or diastolic LV function</li> <li>• Increase in E/e'</li> <li>• Loss of sinus rhythm</li> </ul>	IC IC IIC IIC
Arrhythmogenic cardiomyopathy	<ul style="list-style-type: none"> <li>• Deterioration in ventricular function</li> <li>• Increase in degree of tricuspid regurgitation</li> <li>• Frequent or complex ventricular ectopy</li> </ul>	IC IIC IIC

**Table 4** (continued)

Condition		Level of evidence and strength of recommendation
Pulmonary arterial hypertension	<ul style="list-style-type: none"> <li>• Any deterioration in RV function</li> <li>• Evidence of rising pulmonary artery pressure</li> <li>• Progressive tricuspid regurgitation</li> </ul>	IC IC IIC
Congenital heart disease		
Tetralogy of Fallot	<ul style="list-style-type: none"> <li>• Deterioration in RV function</li> <li>• Progressive tricuspid regurgitation</li> </ul>	IC IIC
Transposition of the great arteries (dTGA)	Post arterial switch operation: <ul style="list-style-type: none"> <li>• New LV dysfunction</li> <li>• Progressive dilatation of neo aortic root or aortic regurgitation</li> <li>• If right-sided obstruction, worsening of RV function or progressive TR</li> </ul> Post Senning or Mustard repair: <ul style="list-style-type: none"> <li>• Deterioration in systemic RV function</li> <li>• Progression of systemic tricuspid regurgitation</li> </ul> Post Rastelli operation: <ul style="list-style-type: none"> <li>• New LV dysfunction</li> </ul>	IC IIC IIC IC IIC IIC
Congenitally corrected TGA	<ul style="list-style-type: none"> <li>• New or deteriorating systemic RV dysfunction</li> <li>• Progressive systemic tricuspid regurgitation</li> </ul>	IC IIC
Fontan circulation	<ul style="list-style-type: none"> <li>• New or deteriorating ventricular dysfunction</li> <li>• New or deteriorating atrioventricular valve regurgitation</li> <li>• Loss of sinus rhythm</li> </ul>	IIC IIC IIC

Deterioration in ventricular function should be considered as a deterioration compared to the previous study. Any change in valve function should be considered as a change of  $\geq 1$  grade of stenosis or regurgitation

DCM dilated cardiomyopathy, EF ejection fraction, LV left ventricle/ventricular, LVOT left ventricular outflow tract, LVEDd left ventricular end diastolic diameter, PA pulmonary artery, PPCM peripartum cardiomyopathy, RV right ventricle/ventricular, TGA transposition of the great arteries, TOE transoesophageal echocardiography, TR tricuspid regurgitation

<sup>a</sup> CT should be used if fluoroscopy and/or TOE are not diagnostic. It should not be avoided because of the radiation dose in a potentially high risk situation

[40]. Echocardiographic assessment is as for non-pregnant patients.

### Hypertensive disorders of pregnancy

Hypertensive disorders of pregnancy are common, affecting around 10% of pregnancies [40, 41]. The term “Hypertensive disorders of pregnancy”, (HDP) includes chronic hypertension in pregnancy, gestational hypertension and preeclampsia [42]. These conditions are important as they are associated with a two-fold increase in the risk of longer-term cardiovascular disease [44, 45] and a sixfold increase in the risk of developing hypertension within two years of delivery [46]. In general, the BSE only recommends echocardiography if there is a clinical suspicion of heart failure or coarctation of the aorta (IIC) [43].

If echocardiography is performed, the focus should be on the assessment of concentric hypertrophy, left atrial dilatation [47] and diastolic dysfunction [48]. Left ventricular ejection fraction does not appear to be affected by gestational hypertension [48, 49], although global longitudinal strain has been shown to be reduced [50].

### Echocardiography in pregnancy in pre-existing heart disease

#### Valvular heart disease

##### Normal findings in pregnancy

The haemodynamic changes of pregnancy influence the maternal response to and echocardiographic assessment of valve disease. Due to chamber dilatation, the mitral, and tricuspid annuli increase during pregnancy, resulting in mild mitral and tricuspid regurgitation in 28% and 94% cases, respectively. The pulmonary annulus also dilates, resulting in mild pulmonary regurgitation in 94% of cases. These changes have mostly resolved by six weeks post-partum but can take up to six months to fully resolve [51]. The aortic root diameter increases a small amount but remains within normal limits. The annulus does not change, and so aortic regurgitation is not a feature of normal pregnancy [51].

Transvalvular gradients increase throughout pregnancy [6, 52, 53], reflecting the increasing stroke volume [6]. However, it should be remembered the standard cut off values to determine severity of valve stenosis are based on normal flow rates outside of pregnancy. Velocity-derived pressure gradients correlate less well with

stenosis severity, though valve area calculations using the Bernoulli equation and assessment of the dimensionless valve index (DVI) are still valid [52, 53]. Assessment of stenosis using the modified Bernoulli equation alone can overestimate the stenosis and should be avoided, due to the increased flow state. Indexing of AVA to current weight derived BSA should also be avoided.

In general, due to the reduction in systemic vascular resistance, regurgitant valve lesions are better tolerated in pregnancy than stenotic ones, and are associated with better outcomes [54, 55].

Assessment of valve disease should follow previously published BSE guidance [56–58]. However, there are some echocardiographic parameters that are particularly important in assessing valvular heart disease during pregnancy. These are detailed below and shown in Table 5.

**Aortic stenosis**

Aortic stenosis in women of childbearing age in high income countries is most often related to bicuspid aortic valve disease, either operated or unoperated. Rheumatic heart disease is more common in women from low and middle income countries. Echocardiography is key in the assessment of the ability of the left ventricle to cope as cardiac output increases. Systolic and diastolic function, filling pressure, left atrial size, mitral regurgitation and pulmonary artery pressure should be assessed. In those with bicuspid aortic valve disease and/or previously identified aortic dilatation, the aortic root and ascending aorta should be measured [59].

**Mitral stenosis**

Mitral stenosis in women of childbearing age is most commonly due to rheumatic heart disease [54] but can

also be seen in parachute mitral valve, or after mitral valve repair (or atrioventricular valve repair in the context of atrioventricular septal defect). Rheumatic mitral stenosis remains prevalent in patients born in low and middle income countries, and not uncommonly presents for the first time late in the second trimester, when the cardiac output starts to peak and even women with moderate mitral stenosis can decompensate in pregnancy.

Careful assessment is needed of the underlying cause of mitral stenosis, the severity, and other associated valvar or structural lesions. Reporting the mean gradient (and heart rate) is most helpful, acknowledging that the gradient will increase as pregnancy progresses. In cases of newly diagnosed mitral stenosis in pregnancy, sole use of the mean gradient can overestimate the degree of stenosis. Assessment of effective valve orifice area by planimetry (if easily obtained) or continuity equation is preferred to the pressure half time method which is less reliable in pregnancy. Echocardiographic assessment should focus on left ventricular filling pressure, left atrial size and thrombus, pulmonary artery pressure, and right heart size and function.

The morphology of the stenotic mitral valve should be carefully assessed, including feasibility of balloon mitral valvuloplasty, since it is usually only the rheumatic valve that is suitable for percutaneous valvuloplasty.

**Pulmonary stenosis**

Pulmonary stenosis in pregnancy is rare. Most cases are congenital and have been treated in childhood. Where seen it is generally well tolerated as long as RV function is maintained [60]. Echocardiographic assessment should focus on RV systolic function. If impairment is present, surveillance may be required. If decompensation occurs

**Table 5** Key measurements for the serial echocardiographic assessment of valves in pregnancy, which most affect decision making (see text)

	Left heart measurements	Right heart measurements
Mitral stenosis	Mean gradient	Estimation of PAP
Mitral regurgitation	Degree of MR LV size and function	Estimation of PAP
Aortic stenosis	LV function	Estimation of PAP
Aortic regurgitation	LV size and function Note if aortic root dilation is cause	Estimation of PAP
Tricuspid regurgitation		Degree of TR RV size and function
Pulmonary stenosis		RV size function
Pulmonary regurgitation		RV size and function Degree of TR Estimation of PAP if PH

LV left ventricle, PAP pulmonary artery pressure, PH pulmonary hypertension, RV right ventricle, TR tricuspid regurgitation, MR mitral regurgitation

in severe pulmonary stenosis (peak gradient >64 mmHg) during pregnancy, balloon pulmonary valvuloplasty may be indicated.

### **Mitral regurgitation**

Most mitral regurgitation in women of childbearing age is either due to mitral valve prolapse, secondary to annular dilation, or rheumatic heart disease [55, 61]. The benefit of the reduction in afterload in mitral regurgitation is offset by the expansion in blood volume, which together with chamber and annular dilation results in an increased regurgitant volume. Echocardiographic focus should be on left ventricular size, systolic and diastolic function, filling pressure, left atrial size, progression of mitral regurgitation and estimation of PA pressure.

### **Aortic regurgitation**

Aortic regurgitation in women of childbearing age is most commonly due to bicuspid aortic valve disease, including those with previous valvotomy or balloon valvuloplasty. Rare causes include aortopathy-related annular dilation, cusp prolapse, previous endocarditis, or rheumatic valve disease. In aortic regurgitation the reduction in systemic vascular resistance and increased heart rate of pregnancy reduces the effective regurgitant volume. It is rarely problematic and maternal and fetal risks are low [55, 61]. Echocardiographic focus should be on left ventricular size, systolic and diastolic function, filling pressure, progression of aorta size and/or aortic regurgitation and estimation of PA pressure.

### **Pulmonary regurgitation**

In pregnancy, pulmonary regurgitation is usually encountered in women with known congenital heart disease due to repaired Tetralogy of Fallot, pulmonary atresia or previous pulmonary valvotomy/valvuloplasty for congenital pulmonary stenosis. It is well tolerated if the right ventricular function is good [61, 62]. Rarely it may be secondary to pulmonary arterial hypertension, which carries a very high maternal risk. If the right ventricle dilates, tricuspid regurgitation may develop or worsen. Echocardiographic focus should be on diagnosing the underlying aetiology, right ventricular size and systolic function and degree of tricuspid regurgitation.

### **Tricuspid regurgitation**

In women of child-bearing age, tricuspid regurgitation may be due to congenital heart disease, such as Ebstein's anomaly, or secondary to an unrepaired atrial septal defect or pulmonary regurgitation, when the right ventricle and tricuspid annulus are dilated. It may also be acquired, as a post intervention phenomenon

(post-surgical repair of ventricular septal defect (VSD), or due to a transvalvar pacing lead), or due to previous endocarditis or trauma. Primary tricuspid regurgitation often progresses in pregnancy due to the volume load and annular dilatation. Echocardiographic focus should be on right ventricular size, systolic function, progression of regurgitation and any associated lesion [61].

### **Prosthetic valves**

Forward flow velocities are marginally increased across all prosthetic valves in pregnancy, in keeping with the increase in cardiac output. The mean gradient is less flow-dependent and serial assessment of DVI is useful. An abrupt increase in velocity mandates careful assessment in the context of symptoms and new clinical findings. Encountering a high gradient secondary to patient prosthesis mismatch (PPM) de novo in pregnancy, without recourse to any previous post-operative echo, is an uncommon scenario. Leaflet motion is normal in PPM and aortic valve acceleration time will not be significantly prolonged. Quantification of prosthetic valve related regurgitation mirrors assessment for native valves.

Pregnancy in a woman with a tissue valve replacement is well tolerated if left ventricular systolic function is within normal limits and there is no/minimal prosthetic valve dysfunction. Management is similar to that of native valve disease and the prosthetic valve should be assessed in the same way as for the non-pregnant patient.

Pregnancy in a woman with a mechanical valve replacement is associated with significant fetal and maternal morbidity and mortality [63, 64]. Prosthetic valve thrombosis can occur, particularly if a woman chooses to use low molecular weight heparin instead of warfarin (which crosses the placenta and is teratogenic). Frequent (four weekly) echocardiographic surveillance of the valve is important, regardless of the anticoagulation regime. Sudden breathlessness or presentation with a possible thromboembolic event during pregnancy or up to six weeks after delivery mandates same-day echocardiography for careful interrogation of the prosthesis [40].

In patients with prosthetic valves and symptoms suggestive of valve dysfunction, or evidence of an abrupt increase in transvalvar velocities or worsening regurgitation, meticulous assessment of the opening and closing of the valve leaflets for evidence of thrombus (or a vegetation) should be sought. If valve leaflet dysfunction is suspected, other imaging modalities are likely to be needed (fluoroscopy and/or trans-oesophageal echocardiography [TOE], rarely CT). Any suspicion of mechanical valve dysfunction should raise the possibility of valve thrombosis, and trigger urgent clinical review (1C).



### **Cardiomyopathies**

Pre-existing cardiomyopathy in pregnancy may be dilated, arrhythmogenic, hypertrophic or previous peripartum. Each is discussed briefly below.

#### **Dilated cardiomyopathy**

Dilated cardiomyopathy (DCM) seen in pregnancy may be familial or acquired, for example due to previous myocarditis, previous chemotherapy, but also hypertension, diabetes or alcohol. In many cases, the cause may be unknown. Although many will have been diagnosed prior to pregnancy and thus had the opportunity for pre-pregnancy assessment and counselling, some women do not present until the physiological demands of pregnancy precipitate symptoms for the first time.

Many pregnant women with known DCM have a left ventricular ejection fraction >40%, as those with more severe dysfunction (LVEF <30%) [40] are usually counselled against, and may choose not to become pregnant. Nonetheless, pregnancy can precipitate heart failure with a reduction in ventricular function. Left ventricular systolic function must be assessed serially for a decline in function. Global longitudinal strain may be useful in identifying women at higher risk of deterioration, but data are sparse on normal and abnormal cut off values. Echocardiography assessment should focus upon the DCM assessment as per non-pregnant patients [65].

#### **Hypertrophic cardiomyopathy**

Pregnancy in women with hypertrophic cardiomyopathy is well tolerated if left ventricular systolic and diastolic function are within normal limits and there is no significant left ventricular outflow tract (LVOT) obstruction [66, 67]. In women at higher risk, the increased load of pregnancy can result in decompensation, as can the onset of atrial arrhythmia. Echocardiographic focus is as per previously described guidance [47] and should include left ventricular systolic and diastolic function, assessment for left ventricular outflow tract (LVOT) obstruction and serial assessment of E/e' [68].

#### **Arrhythmogenic cardiomyopathy**

Arrhythmogenic cardiomyopathy primarily affects the right ventricle and is rare. Heart failure in pregnancy can occur in women with previous ventricular impairment [69]. Focus should be on left and right ventricular systolic function, as the left ventricle is frequently involved.

#### **Previous peripartum cardiomyopathy**

Approximately half of women who suffer from PPCM will recover [70]. Some may choose to have another pregnancy and, in those that do, the recurrence rate is

approximately 25%. This figure rises to two thirds in those who have residual left ventricular systolic dysfunction (ejection fraction <45%) [71]. Echocardiographic assessment is as for DCM above [65].

#### **Pulmonary arterial hypertension**

Pulmonary arterial hypertension (PAH) carries an extremely high maternal risk, when due to elevated pulmonary vascular resistance, even in the era of selective pulmonary vasodilator therapy. Echocardiographic assessment should form part of specialised, frequent clinical assessment throughout pregnancy and the early puerperium, and focus on surveillance of right ventricular size, function and estimated pulmonary artery pressure [40].

#### **Congenital heart disease**

Understanding the anatomy and physiology of the congenital lesion, details of any repair and the effects of the physiological changes of pregnancy on this are essential [72]. The BSE and UKMCS advocate that pregnant women with complex lesions should be scanned by appropriately trained and experienced echocardiographers.

#### **Septal defects and left to right shunts**

Isolated small or repaired septal defects and left to right shunts with no significant sequelae, including partial anomalous pulmonary venous drainage, atrial and ventricular septal defects and patent arterial ducts do not usually require echocardiographic surveillance during pregnancy. Unrepaired larger atrial septal defects are well tolerated in pregnancy if right ventricular function and pulmonary vascular resistance are normal. The increased volume load of pregnancy will result in an increase in left to right shunting, but this is ameliorated by a reduction in systemic vascular resistance. Tricuspid regurgitation may develop and should be assessed accordingly. Atrioventricular septal defects will usually have been repaired prior to pregnancy. Any residual left atrioventricular valve disease should be approached as per the mitral valve and any residual atrial septal defect as an unrepaired atrial septal defect.

#### **Tetralogy of fallot**

Most patients will have undergone surgical repair and may have had a further pulmonary valve replacement for pulmonary regurgitation. They may also have had intervention to the branch pulmonary arteries and/or tricuspid valve. Patients with native pulmonary valves in situ not uncommonly have chronic severe pulmonary regurgitation. Echocardiographic focus should be on assessing

right ventricular function, preferably using strain, and comparing serial measurements [73]. Pulmonary regurgitation does not usually increase significantly but tricuspid regurgitation is common and may cause symptoms if severe. Pregnancy is usually well tolerated if right ventricular function is good [74].

#### **Transposition of the great arteries (dTGA)**

Most patients undergoing surgical correction from the 1990s onwards will have had an arterial switch repair, which involves a switch at great artery level with reimplantation of the coronary buttons. Post-operatively, the cardiac chambers are in their usual positions. Complications, such as supra-pulmonary stenosis, neo-aortic root dilatation, aortic regurgitation and left ventricular dysfunction, should be assessed in the same way as in the non-pregnant patient.

Pre-1990s, surgery for TGA involved rerouting systemic and pulmonary venous return at atrial level, with a Mustard or Senning repair, resulting in a systemic morphological right ventricle, systemic tricuspid valve, and a subpulmonary left ventricle. Late complications include systemic right ventricular dysfunction, systemic tricuspid regurgitation, and arrhythmias. Pregnancy can be associated with clinically significant progressive right ventricular dilatation and dysfunction, as well as an increase in systemic tricuspid regurgitation [75].

A Rastelli repair may be performed to repair transposition of the great arteries with VSD and pulmonary stenosis. The VSD is closed to commit the left ventricle to the aorta, the pulmonary artery is ligated proximally, and a right ventricle to pulmonary artery conduit is placed, resulting in a systemic morphological left ventricle. Assuming good ventricular and conduit function, pregnancy is generally well tolerated, with slightly increased forward flow through the conduit as the cardiac output rises.

#### **Congenitally corrected TGA**

In congenitally corrected TGA (ccTGA) the morphological right ventricle is the systemic ventricle and there is a subpulmonary left ventricle. Progressive systemic right ventricular dilatation and dysfunction compared to baseline may occur with pregnancy. An increase in systemic (tricuspid) valve regurgitation may also be noted.

#### **Fontan circulation**

A Fontan circulation is created to palliate the functionally single ventricle heart. The single ventricle supports the systemic circulation, with passive flow to the pulmonary

arteries. The efficiency of this limited cardiac output circulation is dependent on adequate filling, and maintenance of sinus rhythm. Pregnancy is associated with an increased risk of heart failure, arrhythmia, haemorrhage and thrombosis [76]. Echocardiographic assessment should focus on detecting any progression of ventricular dysfunction and/or valvar regurgitation.

#### **Echocardiography triage and surveillance during and after pregnancy**

Echocardiography triage and surveillance recommendations for pregnancy are shown in Table 6. Guidance in the literature is somewhat limited for many lesions and so we present our consensus view, based on experience and the likelihood of deterioration during pregnancy. The only conditions where first trimester screening is necessary are in patients presenting de novo, and those who are at very high risk, e.g. those with severe left ventricular systolic impairment, severe left ventricular outflow tract obstruction with symptoms, mechanical prosthetic valves, and high risk aortopathies. In higher risk women, echocardiographic surveillance needs to increase in frequency as pregnancy progresses. Monitoring frequency should increase if cardiac symptoms worsen, the clinical scenario changes or if echocardiographic parameters deteriorate. Conditions by risk, according to the European Society of Cardiology guidelines, are shown in Table 7 [40].

Though the symptoms and signs of cardiac decompensation are similar to the symptoms and clinical findings of normal pregnancy, breathlessness out of proportion to gestation, orthopnoea, paroxysmal nocturnal dyspnoea, resting sinus tachycardia >100 beats per minute, and clinical signs of heart failure, all warrant prompt cardiology assessment and consideration of echocardiography. In addition, N-terminal pro hormone brain natriuretic peptide (NT pro-BNP) levels are only slightly elevated in normal pregnancy, more so in pre-eclampsia and markedly so in heart failure, including PPCM [77]. Therefore echocardiography should be undertaken as a clinical priority in pregnant women with symptoms or signs of heart failure, an abnormal 12 lead electrocardiogram or an NT pro-BNP in the heart failure range. It is important to note that echocardiography cannot exclude PE, acute coronary syndrome or aortic dissection, and other imaging modalities should be sought. Rapid increases in afterload due to hypertension, particularly associated with large fluid shifts such as those that occur post-partum, can result in worsening mitral regurgitation that can become clinically significant, as shown in Fig. 1.

**Table 6** Suggested frequency of echocardiography surveillance during and after pregnancy [27, 39, 40]

Condition	During pregnancy	Post-partum	Level of evidence and strength of recommendation
Valvular disorders <sup>a</sup>	As early as possible if not performed pre-pregnancy		
Stenotic lesions	Mild AS: Once mid gestation only	3–5 years	IlaC
	Mild MS: Once 2nd and 3rd trimester	3–5 years	IlaC
	Moderate AS: Once 2nd and 3rd trimester and prior to delivery	12 months	IlaC
	Severe AS: 4–8 weekly depending on symptoms, and prior to delivery	Pre-discharge, then 3 months	IC
	Moderate and severe MS: 4–8 weekly depending on symptoms, and prior to delivery	Pre-discharge, then 3 months	IC
Regurgitant lesions	Mild AR/MR, moderate PR/TR: Once mid gestation	As per usual follow-up	IlaC
	Moderate AR/MR, severe PR/TR: Once 2nd and 3rd trimester	6 months	IlaC
Tissue prostheses	Severe: S Severe AR/MR: 8 weekly depending on symptoms	Pre-discharge, then 6 months	IlaC
Mechanical prostheses	As for native valve disease 4 weekly if functionally normal	Pre-discharge, then 1–2 months	IC IC
Cardiomyopathy			
Dilated cardiomyopathy	4–8 weekly, increasing to 1–4 weekly, if LVEF <40%	Pre-discharge, then 4–8 weeks, depending on ventricular function/recovery	IC
Hypertrophic cardiomyopathy	If symptomatic, systolic dysfunction, impaired diastolic function with raised filling pressure or obstruction, 4 weekly, otherwise once only	Pre-discharge, then 4–8 weeks if complicated or obstruction, otherwise 3–6 months	IlaC
ARVC	4–8 weekly, depending on RV function	Pre-discharge, then 4 weeks, if impaired RV function, otherwise 3–6 months	IlaC
Previous peripartum cardiomyopathy, with recovered LV function	End first trimester and end second trimester	Prior to discharge and one month after delivery	IC
Inherited aortopathies	4–12 weekly, depending on clinical scenario, as determined by the pregnancy heart team <sup>b</sup>	Pre-discharge, then 4–12 weeks, depending on clinical scenario	IC
Congenital heart disease <sup>c</sup>			
ASD with right heart dilatation, unrepaired	Once, not required if small	As per usual follow-up	IlaC
Fallot	If impaired RV function 4–8 weekly, otherwise once	Pre-discharge and 4–8 weeks if impaired RV function, otherwise 3–6 months	IlaC
TGA with systemic right ventricle	4–8 weekly, depending on clinical scenario	Pre-discharge, then 4–8 weeks	IlaC
Fontan	8 weekly, depending on clinical scenario/once	Pre-discharge only impaired ventricular function, otherwise 3–6 months	IlaC
Coronary artery disease	Once only, if no residual ventricular dysfunction	As per usual follow up	IIC
Hypertensive disorders of pregnancy	Only if suspicion of heart failure, or coarctation of the aorta	Not usually indicated	IC
Pulmonary arterial hypertension	4 weekly, increasing to 2–4 weekly, depending on RV function, as determined by the pregnancy heart team	Prior to discharge and at 4–8 weeks	IC

**Table 6** (continued)

ARVC arrhythmogenic right ventricular cardiomyopathy, AR aortic regurgitation, AS aortic stenosis, ASD atrial septal defect, EF ejection fraction, LV left ventricular, MR mitral regurgitation, MS mitral stenosis, PR pulmonary regurgitation, RV right ventricular, TGA transposition of the great arteries, TR tricuspid regurgitation

<sup>a</sup> Degree of valve stenosis/regurgitation is based on pre-pregnancy scan. Post-partum follow up of mild and moderate valve disease can, in general, be as per BSE guidelines. In more severe disease, the pregnancy or simply the passage of time may have progressed the disease and earlier follow up is advised

<sup>b</sup> Frequency depends on the risk of dilatation, which is related to the aortic diameter, the underlying condition and the family history of dissection

<sup>c</sup> Dictated by ventricular function and valve disease

**Table 7** Modified World Health Organization (WHO) classification of maternal cardiovascular risk with maternal cardiac event rate

mWHO I (no risk)	mWHO II (low risk)	mWHO II-III (moderate risk)	mWHO III (high risk)	mWHO IV (pregnancy contraindicated)
Mild		Native/tissue valve disease not WHO I or IV	Mechanical valve	Severe MS Severe symptomatic AS
-Pulmonary stenosis -Mitral valve prolapse			Moderate MS Severe asymptomatic AS	
Repaired simple shunts	Unoperated simple shunts	Mild LV impairment (EF > 45%) HCM	Moderate LV impairment (EF 30–45%) Systemic RV, good/mildly decreased function Recovered PPCM	Severe systemic ventricular dysfunction (EF < 30%/NYHA class III–IV) or > / = moderate if systemic RV PPCM, not recovered
PDA	Repaired Tetralogy of Fallot	AVSD Repaired coarctation	Fontan Unrepaired cyanotic heart disease/complex heart disease	Fontan with complication Severe (re)coarctation
Atrial or ventricular ectopic beats	Supraventricular arrhythmias Turner syndrome, no aortic dilatation	Marfan/HTA, no aortic dilatation Bicuspid aortopathy < 45 mm	VT Moderate aortic dilatation	Severe aortic dilatation Vascular Ehlers–Danlos
2.5–5%	5.7–10.5%	10–19%	19–27%	PH 40–100%

AS aortic stenosis, AVSD atrioventricular septal defect, EF ejection fraction, HCM hypertrophic cardiomyopathy, LV left ventricle, MS mitral stenosis, PDA patent ductus arteriosus, PH pulmonary hypertension, PPCM peripartum cardiomyopathy, RV right ventricle, VT ventricular tachycardia

Adapted from [40]

**Practical advice on scanning pregnant women**


Some special considerations are required for performing echocardiography in pregnant women. As the uterus and breasts increase in size as pregnancy advances, the ability to acquire high quality images decreases. The use of breath-hold will help improve image acquisition. The subcostal view becomes very difficult with advancing pregnancy. A patient > 20 weeks gestation should not be placed in the supine position, to avoid caval compression by the gravid uterus. Not only will this affect measurements dependent on cardiac output, but the patient may become hypotensive and syncopal.

Moving into the appropriate position for scanning may be difficult for the woman and breast tissue may be tender. It is therefore important to ensure that the patient is comfortable and feels at ease with the echocardiographer.

It is helpful to take every measurement possible and assess lesions from multiple scanning views while image quality is good as the quality may deteriorate later in the pregnancy. Serial scans are often needed and so it is helpful to have scans performed by the same echocardiographer wherever possible to reduce interobserver variability.

**Conclusion**

In response to the altered loading conditions of pregnancy, the normal heart undergoes reversible remodelling that may take weeks or months to resolve post-partum. These pregnancy-induced cardiovascular changes can stress maternal physiology sufficiently to adversely affect women with pre-existing cardiac disease. Pregnancy can also unmask previously undiagnosed cardiac conditions,



**Fig. 1** Post-partum hypertension on a background of mild anterior mitral valve leaflet prolapse with trivial mitral regurgitation, leading to severe mitral regurgitation and pulmonary oedema in a woman 24 h after delivery. **A** and **C** show the post-partum images. **B** and **D** show the same patient 6 months later on no medication

or precipitate de novo disease. Sonographers and clinicians should understand the normal echocardiographic findings in pregnancy and recognise the abnormal changes that should precipitate prompt clinical review. As a safe, easily accessible imaging modality, echocardiography is crucial for the rapid diagnosis and surveillance of maternal heart disease, playing a key role in improving maternal outcomes.

**Abbreviations**

ARVC	Arrhythmogenic right ventricular cardiomyopathy
ASD	Atrial septal defect
AS	Aortic stenosis
AV	Atrioventricular
AVSD	Atrioventricular septal defect
BSE	British Society of Echocardiography
ccTGA	Congenitally corrected transposition of the great arteries
DCM	Dilated cardiomyopathy

EF	Ejection fraction
GLS	Global longitudinal strain
HCM	Hypertrophic cardiomyopathy
HDP	Hypertensive disorders of pregnancy
IVSd	Interventricular septal wall thickness in diastole
LA	Left atrium
LV	Left ventricle
LVEDd	Left ventricular end diastolic dimension
LVEDvol	Left ventricular end diastolic volume
LVESd	Left ventricular end systolic dimension
LVESvol	Left ventricular end systolic volume
LVEF	Left ventricular ejection fraction
LVMi	Left ventricular mass index
LVOT	Left ventricular outflow tract
MR	Mitral regurgitation
MS	Mitral stenosis
NT pro-BNP	N-terminal pro hormone brain natriuretic peptide
PAP	Pulmonary artery pressure
PDA	Patent ductus arteriosus
PH	Pulmonary hypertension
PPCM	Peripartum cardiomyopathy
PE	Pulmonary embolism
PWTd	Posterior wall thickness in diastole
RV	Right ventricular/right ventricle
TASPE	Tricuspid annular plane systolic excursion
TDI	Tissue Doppler imaging
TGA	Transposition of the great arteries
TR	Tricuspid regurgitation
TOE	Trans-oesophageal echocardiography
TTE	Trans-thoracic echocardiography
UKMCS	United Kingdom's Maternal Cardiology Society
VT	Ventricular tachycardia
WHO	World Health Organisation

**Acknowledgements**

Not applicable.

**Author contributions**

DXA and SR devised the concept. All authors contributed to, read, edited and approved the final manuscript.

**Funding**

No funding was received for this guideline.

**Available of data and materials**

Not applicable.

**Declarations****Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that there is no competing interest that could be perceived as prejudicing the impartiality of this guideline.

Received: 5 July 2022 Accepted: 30 March 2023

Published online: 20 April 2023

**References**

- Knight M, et al editors. Saving Lives, Improving Mothers' Care—Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2017–19. National Perinatal Epidemiology Unit, University of Oxford: Oxford; 2019.
- Melchiorre K, Sharma R, Thilaganathan B. Cardiac structure and function in normal pregnancy. *Curr Opin Obstet Gynecol*. 2012;24(6):413–21. <https://doi.org/10.1097/GCO.0b013e328359826f>.
- Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. *Circulation*. 2014;130(12):1003–8. <https://doi.org/10.1161/CIRCULATIONAHA.114.009029>.
- Hunter S, Robson SC. Adaptation of the maternal heart in pregnancy. *Br Heart J*. 1992;68(6):540–3. <https://doi.org/10.1136/hrt.68.12.540>. (PMID:1467047; PMCID: PMC1025680).
- Estensen ME, Beitnes JO, Grindheim G, Aaberge L, Smiseth OA, Henriksen T, Aakhus S. Altered maternal left ventricular contractility and function during normal pregnancy. *Ultrasound Obstet Gynecol*. 2013;41(6):659–66. <https://doi.org/10.1002/uog.12296>.
- Savu O, Jurcuț R, Giuscă S, VanMieghem T, Gussi I, Popescu BA, Ginghină C, Rademakers F, Deprest J, Voigt JU. Morphological and functional adaptation of the maternal heart during pregnancy. *Circ Cardiovasc Imaging*. 2012;5(3):289–97. <https://doi.org/10.1161/CIRCIMAGING.111.970012>.
- Tso G, Lee J, Lui G, Trivedi H, Cohen M, Bernstein P, et al. Range of echocardiographic parameters during Normal Pregnancy. *J Am Coll Cardiol*. 2018;59(13 Supplement):E1301. [https://doi.org/10.1016/S0735-1097\(12\)61302-3](https://doi.org/10.1016/S0735-1097(12)61302-3).
- Melchiorre K, Sharma R, Khalil A, Thilaganathan B. Maternal cardiovascular function in normal pregnancy evidence of maladaptation to chronic volume overload. *Hypertension*. 2016;67(4):754–62. <https://doi.org/10.1161/HYPERTENSIONAHA.115.06667>.
- Cong J, Fan T, Yang X, Squires JW, Cheng G, Zhang L, Zhang Z. Structural and functional changes in maternal left ventricle during pregnancy: a three-dimensional speckle-tracking echocardiography study. *Cardiovasc Ultrasound*. 2015;27(13):6. <https://doi.org/10.1186/1476-7120-13-6>.
- Tsiaras S, Poppas A. Cardiac disease in pregnancy: value of echocardiography. *Curr Cardiol Report*. 2010;12(3):250–6. <https://doi.org/10.1007/s11886-010-0106-9>.
- Gati S, Papadakis M, Papamichael ND, Zaidi A, Sheikh N, Reed M, Sharma R, Thilaganathan B, Sharma S. Reversible de novo left ventricular trabeculations in pregnant women clinical perspective. *Circulation*. 2014;130(6):475–83. <https://doi.org/10.1161/CIRCULATIONAHA.114.008554>.
- Ristić A, Seferović P, Ljubić A, Jovanović I, Ristić G, Pankuweit S, Ostojic M, Maisch B. Pericardial disease in pregnancy. *Herz*. 2003;28:209–15. <https://doi.org/10.1007/s00059-003-2470-3>.
- Gilson GJ, Samaan S, Crawford MH, Qualls CR, Curet LB. Changes in hemodynamics, ventricular remodeling and ventricular contractility during normal pregnancy: a longitudinal study. *Obstet Gynecol*. 1997;89(6):957–62. [https://doi.org/10.1016/s0029-7844\(97\)85765-1](https://doi.org/10.1016/s0029-7844(97)85765-1).
- Papadopoulou E, Kaladaridou A, Agrios J, Matthaïou J, Pamboukas C, Toumanidis S. Factors influencing the twisting and untwisting properties of the left ventricle during normal pregnancy. *Echocardiography*. 2013;00:1–9. <https://doi.org/10.1111/echo.12345>.
- Geva T, Mauer MB, Striker L, Kirshon B, Pivarnik JM. Effects of physiologic load of pregnancy on left ventricular contractility and remodeling. *Am Heart J*. 1997;133:53–9. [https://doi.org/10.1016/s0002-8703\(97\)70247-3](https://doi.org/10.1016/s0002-8703(97)70247-3).
- Poppas A, Shroff SG, Korcarz CE, Hibbard JU, Berger DS, Lindheimer MD, Land RM. Serial assessment of the cardiovascular system in normal pregnancy. Role of arterial compliance and pulsatile arterial load. *Circulation*. 1997;95:2407–15. <https://doi.org/10.1161/01.CIR.95.10.2407>.
- Bamfo FE, Kametas NA, Nicolaïdes KH, Chambers JB. Reference ranges for tissue Doppler measures of maternal systolic and diastolic left ventricular function. *Ultrasound Obstet Gynecol*. 2007;29:414–20. <https://doi.org/10.1002/uog.3966>.
- Mesa A, Jessurun C, Hernandez A, Adam K, Brown D, Vaughn WK, Wilansky S. Left ventricular diastolic function in normal human pregnancy. *Circulation*. 1999;99:511–7. <https://doi.org/10.1161/01.CIR.99.4.511>.
- Harkness A, Ring L, Augustine DX, Oxborough D, Robinson S, Sharma V. Normal reference intervals for cardiac dimensions and function for use in echocardiographic practice: a guideline from the British Society of Echocardiography. *Echo Res Pract*. 2020;7(1):G1–7. <https://doi.org/10.1530/ERP-19-0050>.
- Meah VL, Backx K, Cockcroft JR, Shave RE, Stohr EJ. Left ventricular mechanics in late second trimester of healthy pregnancy. *Ultrasound Obstet Gynecol*. 2019;54:350–8. <https://doi.org/10.1002/uog.20177>.

21. Yoon AJ, Song J, Megalla S, Nazari R, Akinlaja O, Pollack S, Bella JN. Left ventricular torsional mechanics in uncomplicated pregnancy. *Clin Cardiol*. 2011;34(9):543–8. <https://doi.org/10.1002/clc.20942>. (PMID: **21887687**; PMCID: **PMC6652494**).
22. Nagueh SF, Smiseth OA, Appleton CP, Byrd B, Dokainish H, Edvardsen T, Flachskampf FS, Gillebert TC, Klein AL, Lancellotti P, Marino PN, Oh JK, Bogdan AP, Waggoner AD. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2009;29(4):P277–314. <https://doi.org/10.1016/j.echo.2016.01.011>.
23. Fok WY, Chan LY, Wong JT, Yu CM, Lau TK. Left ventricular diastolic function during normal pregnancy: assessment by spectral tissue Doppler imaging. *Ultrasound Obstet Gynecol*. 2006;28(6):789–93. <https://doi.org/10.1002/uog.3849>.
24. Kimura Y, Kato T, Miyata H, Sasaki I, Minamino-Muta E, Nagasawa Y, Numao S, Nagano T, Higuchi T, Inoko M. Left ventricular diastolic function during the normal peripartum period. *Circ J*. 2019;83(11):2265–70. <https://doi.org/10.1253/circj.CJ-19-0501>. (Epub 2019 Sep 22 PMID: **31548443**).
25. Zentner D, du Plessis M, Brennecke S, Wong J, Grigg L, Harrap SB. Deterioration in cardiac systolic and diastolic function late in normal human pregnancy. *Clin Sci (Lond)*. 2009;116(7):599–606. <https://doi.org/10.1042/CS20080142>. (PMID: **18855763**).
26. Del Prado DS, de la Calle M, Valbuena-López SC, Montoro López N, MerásColunga P, Bartha JL, Guzmán-Martínez G. Does the right ventricle experiment morphologic and functional changes similarly to the left ventricle during pregnancy? *Echocardiography*. 2020;37(6):850–7. <https://doi.org/10.1111/echo.14678>. (Epub 2020 May 20 PMID: **32433805**).
27. Sliwa K, van der Meer P, Petrie MC, Frogoudaki A, Johnson MR, Hilfiker-Kleiner D, Hamdan R, Jackson AM, Ibrahim B, Mbakwem A, Tschöpe C, Regitz-Zagrosek V, Omerovic E, Roos-Hesselink J, Gatzoulis M, Tutarel O, Price S, Heymans S, Coats AJS, Müller C, Chioncel O, Thum T, de Boer RA, Jankowska E, Ponikowski P, Lyon AR, Rosano G, Seferovic PM, Bauersachs J. Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. *Eur J Heart Fail*. 2021;23(4):527–40. <https://doi.org/10.1002/ehfj.2133>. (Epub 2021 Mar 17. Erratum in: *Eur J Heart Fail*. 2022 Apr;24(4):733. PMID: **33609068**).
28. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, Modi K, Alexis JD, Ramani GV, Semigran MJ, Haythe J, Markham DW, Marek J, Gorcsan J 3rd, Wu WC, Lin Y, Halder I, Pisarcik J, Cooper LT, Fett JD, IPAC Investigators. Clinical outcomes for peripartum cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). *J Am Coll Cardiol*. 2015;66(8):905–14. <https://doi.org/10.1016/j.jacc.2015.06.1309>.
29. Sugahara M, Kagiyama N, Hasselberg NE, Blauwet LA, Briller J, Cooper L, Fett JD, Hsich E, Wells G, McNamara D, Gorcsan J 3rd, IPAC Investigators. Global left ventricular strain at presentation is associated with subsequent recovery in patients with peripartum cardiomyopathy. *J Am Soc Echocardiogr*. 2019;32(12):1565–73. <https://doi.org/10.1016/j.echo.2019.07.018>.
30. Pacheco C, Tremblay-Gravel M, Marquis-Gravel G, Couture E, Avram R, Desplante O, Bibas L, Simard F, Malhame I, Pulin A, Tran D, Senechal M, Afilalo J, Farand P, Berube L, Jolicouer EM, Ducharme A, Tournoux F. Association between right ventricular dysfunction and adverse outcomes in peripartum cardiomyopathy: insights from the retrospective BRO-HF Quebec Cohort Study. *CJC Paediatric and Congenital Heart Disease May* 24, 2022.
31. Haghikia A, Röntgen P, Vogel-Claussen J, Schwab J, Westenfeld R, Ehlermann P, Berliner D, Podewski E, Hilfiker-Kleiner D, Bauersachs J. Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. *ESC Heart Fail*. 2015;2(4):139–49. <https://doi.org/10.1002/ehf2.12059>. (Epub 2015 Sep 30. PMID: **27774259**; PMCID: **PMC5054874**).
32. Karaye KM, Lindmark K, Henein M. Right ventricular systolic dysfunction and remodelling in Nigerians with peripartum cardiomyopathy: a longitudinal study. *BMC Cardiovasc Disord*. 2016;16(27):16–27. <https://doi.org/10.1186/s12872-016-0204-8>.
33. Blauwet LA, Delgado-Montero A, Ryo K, Marek JJ, Alharethi R, Mather PJ, et al. Right ventricular function in peripartum cardiomyopathy at presentation is associated with subsequent left ventricular recovery and clinical outcomes. *Circ Heart Fail*. 2016;9(5):e002756. <https://doi.org/10.1161/CIRCHEARTFAILURE.115.002756>.
34. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. *Am Heart J*. 2006;152(3):509–13. <https://doi.org/10.1016/j.ahj.2006.02.008>. (PMID: **16923422**).
35. Knight M, et al editors. Saving Lives, Improving Mothers' Care—Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2015–17. National Perinatal Epidemiology Unit, University of Oxford: Oxford; 2022.
36. Augustine DX, Coates-Bradshaw LD, Willis J, Harkness A, Ring L, Grapsa J, Coghlan G, Kaye N, Oxborough D, Robinson S, Sandoval J, Rana BS, Siva A, Nihoyannopoulos P, Howard LS, Fox K, Bhattacharyya S, Sharma V, Steeds RP, Mathew T. Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. *Echo Res Pract*. 2018;5(3):G11–24. <https://doi.org/10.1530/ERP-17-0071>.
37. Kamel H, Roman MJ, Pitcher A, Devereux RB. Pregnancy and the risk of aortic dissection or rupture: a cohort-crossover analysis. *Circulation*. 2016;134(7):527–33. <https://doi.org/10.1161/CIRCULATIONAHA.116.021594>. (Epub 2016 Aug 4. PMID: **27492904**; PMCID: **PMC4987245**).
38. Braverman AC, Mittauer E, Harris KM, Evangelista A, Pyeritz RE, Brinster D, Conklin L, Suzuki T, Fanola C, Ouzounian M, Chen E, Myrmet L, Bekerredjian R, Hutchison S, Coselli J, Gilon D, O'Gara P, Davis M, Isselbacher E, Eagle K. Clinical features and outcomes of pregnancy-related acute aortic dissection. *JAMA Cardiol*. 2021;6(1):58–66. <https://doi.org/10.1001/jamacardio.2020.4876>. (PMID: **33052376**; PMCID: **PMC7557715**).
39. Curtis SL, Swan L. Aortopathy in pregnancy. *Heart*. 2022;108:1851–7. <https://doi.org/10.1136/heartjnl-2021-319828>.
40. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C, Cifkova R, DeBonis M, Lung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Peiper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simuncini T, Swan L, Warnes CA. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J*. 2018;39(34):3165–241. <https://doi.org/10.1093/eurheartj/ehy340>.
41. Ramlakhan KP, Johnson MR, Roos-Hesselink JW. Pregnancy and cardiovascular disease. *Nat Rev Cardiol*. 2020;17(11):718–31. <https://doi.org/10.1038/s41569-020-0390-z>.
42. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. *Hypertension*. 2018;72(1):24–43. <https://doi.org/10.1161/HYPERTENSIONAHA.117.10803>.
43. Bennett S, Stout M, Ingram T, Pearce K, Griffiths T, Duckett S, Heatlie G, Thompson P, Tweedie J, Sopala J, Ritzmann, Victor K, Skipper J, Shah BN, Robinson S, Potter A, Augustine DX, Colebourn CL. Clinical Indications and Triaging for Adult Transthoracic Echocardiography: A Consensus Statement by the British Society of Echocardiography in Collaboration with The British Heart Valve Society. *Echo Research and Practice* 2022 (in press).
44. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. *Lancet*. 2005;366(9499):1797–803. [https://doi.org/10.1016/S0140-6736\(05\)67726-4](https://doi.org/10.1016/S0140-6736(05)67726-4). (PMID: **16298217**).
45. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. *Am Heart J*. 2008;156(5):918–30. <https://doi.org/10.1016/j.ahj.2008.06.042>.
46. Giorgione V, Ridder A, Kalafat E, Khalil A, Thilaganathan B. Incidence of postpartum hypertension within 2 years of a pregnancy complicated by pre-eclampsia: a systematic review and meta-analysis. *BJOG*. 2021;128(3):495–503. <https://doi.org/10.1111/1471-0528.16545>. (Epub 2020 Oct 21 PMID: **32981216**).
47. Mattioli AV, Pennella S, Demaria F, Farinetti A. Atrial remodeling in pregnant hypertensive women: comparison between chronic and gestational hypertension. *Open Cardiovasc Med J*. 2012;6:9–14. <https://doi.org/10.2174/1874192401206010009>. (PMID: **22431946**; PMCID: **PMC3293156**).
48. Muthyala T, Mehrotra S, Sikka P, Suri V. Maternal cardiac diastolic dysfunction by doppler echocardiography in women with preeclampsia. *J Clin*

- Diagn Res. 2016;10(8):QC01–3. <https://doi.org/10.7860/JCDR/2016/17840.8220>.
49. Castleman JS, Ganapathy R, Taki F, Lip GY, Steeds RP, Kotecha D. Echocardiographic structure and function in hypertensive disorders of pregnancy: a systematic review. *Circ Cardiovasc Imaging*. 2016;9(9):e004888. <https://doi.org/10.1161/CIRCIMAGING.116.004888>. (PMID: 27609819).
  50. O'Driscoll JM, Giorgione V, Edwards JJ, Wiles JD, Sharma R, Thilaganathan B. Myocardial mechanics in hypertensive disorders of pregnancy: a systematic review and meta-analysis. *Hypertension*. 2022;79(2):391–8. <https://doi.org/10.1161/HYPERTENSIONAHA.121.18123>. (Epub 2021 Nov 17 PMID: 35020458).
  51. Campos O. Doppler echocardiography during pregnancy: physiological and abnormal findings. *Echocardiography*. 1996;13(2):135–46. <https://doi.org/10.1111/j.1540-8175.1996.tb00881>.
  52. Samiei N, Amirsardari M, Rezaei Y, Parsae M, Kashfi F, Hantoosh Zadeh S, Beikmohamadi S, Fouladi M, Hosseini S, Peighambari MM, Mohebbi A. Echocardiographic evaluation of hemodynamic changes in left-sided heart valves in pregnant women with valvular heart disease. *Am J Cardiol*. 2016;118(7):1046–52. <https://doi.org/10.1016/j.amjcard.2016.07.005>. (Epub 2016 Jul 18 PMID: 27506332).
  53. Siegmund AS, Pieper PG, Mulder BJM, Sieswerda GT, van Dijk APJ, Roos-Hesselink JW, Jongbloed MRM, Konings TC, Bouma BJ, Groen H, Sollie-Szarynska KM, Kampman MAM, Bilardo CM, van Veldhuisen DJ, Aalberts JJJ. Doppler gradients, valve area and ventricular function in pregnant women with aortic or pulmonary valve disease: left versus right. *Int J Cardiol*. 2020;306:152–7. <https://doi.org/10.1016/j.ijcard.2019.11.118>.
  54. Van Hagen IM, Thorne SA, Taha N, Youssef G, Elnagar A, Gabriel H, ElRakshy Y, lung B, Johnson MR, Hall R, Roos-Hesselink JW, ROPAC Investigators and EORP Team. Pregnancy outcomes in women with rheumatic mitral valve disease: results from the Registry of Pregnancy and Cardiac Disease. *Circulation*. 2018;137:806–16. <https://doi.org/10.1161/CIRCULATIONAHA.117.032561>.
  55. Ducas RA, Javier DA, D'Souza R, Silversides CK, Tsang W. Pregnancy outcomes in women with significant valve disease: a systematic review and meta-analysis. *Heart*. 2020;106(7):512–9. <https://doi.org/10.1136/heartjnl-2019-315859>.
  56. Robinson S, Ring L, Augustine DX, Rehrhaj S, Oxborough D, Harkness A, Lancellotti P, Rana B. The assessment of mitral valve disease: a guideline from the British Society of Echocardiography. *Echo Res Pract*. 2021;8(1):G87–136. <https://doi.org/10.1530/ERP-20-0034>. (PMID: 34061768; PMCID: PMC8495880).
  57. Ring L, Shah BN, Bhattacharyya S, Harkness A, Belham M, Oxborough D, Pearce K, Rana BS, Augustine DA, Robinson, Tribouillo C. Echocardiography assessment of aortic stenosis: a practical guideline from the British Society of Echocardiography. *Echo Res Pract*. 2021;8(1): G19–G59. <https://doi.org/10.1530/ERP-20-0035>.
  58. Zaidi A, Oxborough D, Augustine DX, Bedair R, Harkness A, Rana B, Robinson S, Badano LP. Echocardiographic assessment of the tricuspid and pulmonary valves: a practical guideline from the British Society of Echocardiography. *Echo Res Pract*. 2020;7(4):G95–122. <https://doi.org/10.1530/ERP-20-0033>. (PMID: 33339003; PMCID: PMC8052586).
  59. Orwat S, Diller GP, van Hagen IM, Schmidt R, Tobler D, Greutmann M, Jonkatiene R, Elnagar A, Johnson MR, Hall R, Roos-Hesselink JW, Baumgartner H, ROPAC Investigators. Risk of pregnancy in moderate and severe aortic stenosis: from the multinational ROPAC registry. *J Am Coll Cardiol*. 2016;68(16):1727–37. <https://doi.org/10.1016/j.jacc.2016.07.750>.
  60. Drenthen W, Pieper PG, Roos-Hesselink JW, Schmidt AC, Mulder BJ, van Dijk AP, Vliegen HW, Sollie KM, Voors AA, Ebels T, van Veldhuisen DJ, ZAHARA investigators. Non-cardiac complications during pregnancy in women with isolated congenital pulmonary valvar stenosis. *Heart*. 2006;92(12):1838–43. <https://doi.org/10.1136/hrt.2006.093849>. (Epub 2006 Jul 3. PMID: 16818485; PMCID: PMC1861275).
  61. Pfaller B, Dave Javier A, Grewal J, Gabarin N, Colman J, Kiess M, Wald RM, Sermer M, Siu SC, Silversides CK. Risk associated with valvular regurgitation during pregnancy. *J Am Coll Cardiol*. 2021;77(21):2656–64. <https://doi.org/10.1016/j.jacc.2021.03.327>. (PMID: 34045022).
  62. Khairy P, Ouyang DW, Fernandes SM, Lee-Parritz A, Economy KE, Landzberg MJ. Pregnancy outcomes in women with congenital heart disease. *Circulation*. 2006;113(4):517–24. <https://doi.org/10.1161/CIRCULATIONAHA.105.589655>. (PMID: 16449731).
  63. van Hagen IM, Roos-Hesselink JW, Ruys TP, Merz WM, Goland S, Gabriel H, Lelonek M, Trojnaraska O, Al Mahmeed WA, Balint HO, Ashour Z, Baumgartner H, Boersma E, Johnson MR, Hall R, ROPAC Investigators and the EURObservational Research Programme (EORP) Team\*. Pregnancy in women with a mechanical heart valve: data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). *Circulation*. 2015;132(2):132–42. <https://doi.org/10.1161/CIRCULATIONAHA.115.015242>. (Epub 2015 Jun 22 PMID: 26100109).
  64. Vause S, Clarke B, Tower CL, Hay C, Knight M, on behalf of UKOSS. Pregnancy outcomes in women with mechanical prosthetic heart valves: a prospective descriptive population based study using the United Kingdom Obstetric Surveillance System (UKOSS) data collection system. *BJOG*. 2017;124(9):1411–9. <https://doi.org/10.1111/1471-0528.14478>. (Epub 2016 Dec 26 PMID: 28019065).
  65. Mathew T, Williams L, Navaratnam G, Rana B, Wheeler R, Collins K, Harkness A, Jones R, Knight D, O'Gallagher K, Oxborough D, Ring L, Sandoval J, Stout M, Sharma V, Steeds RP, British Society of Echocardiography Education Committee. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. *Echo Res Pract*. 2017;4(2):G1–13. <https://doi.org/10.1530/ERP-16-0037>. (PMID: 28592613; PMCID: PMC5574280).
  66. Thaman R, Varnava A, Hamid MS, Firoozi S, Sachdev B, Condon M, Gimeno JR, Murphy R, Elliott PM, McKenna WJ. Pregnancy related complications in women with hypertrophic cardiomyopathy. *Heart*. 2003;89(7):752–6. <https://doi.org/10.1136/heart.89.7.752>. (PMID: 12807849; PMCID: PMC1767741).
  67. Goland S, van Hagen IM, Elbaz-Greener G, Elkayam U, Shotan A, Merz WM, Enar SC, Gaisin IR, Pieper PG, Johnson MR, Hall R, Blatt A, Roos-Hesselink JW. Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). *Eur Heart J*. 2017;38(35):2683–90. <https://doi.org/10.1093/eurheartj/ehx189>. (PMID: 28934836).
  68. Turvey L, Augustine DX, Robinson S, Oxborough D, Stout M, Smith N, Harkness A, Williams L, Steeds RP, Bradlow W. Transthoracic echocardiography of hypertrophic cardiomyopathy in adults: a practical guideline from the British Society of Echocardiography. *Echo Res Pract*. 2021;8(1):G61–86. <https://doi.org/10.1530/ERP-20-0042>.
  69. Hodes AR, Tichnell C, Te Riele AS, Murray B, Groeneweg JA, Sawant AC, Russell SD, van Spaendonck-Zwarts KY, van den Berg MP, Wilde AA, Tandri H, Judge DP, Hauer RN, Calkins H, van Tintelen JP, James CA. Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. *Heart*. 2016;102(4):303–12. <https://doi.org/10.1136/heartjnl-2015-308624>.
  70. Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM, Maggioni AP, Laroche C, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, Roos-Hesselink JW, Seferovic P, van Spaendonck-Zwarts K, Mbakwem A, Böhm M, Mouquet F, Pieske B, Johnson MR, Hamdan R, Ponikowski P, Van Veldhuisen DJ, McMurray JJV, Bauersachs J. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. *Eur Heart J*. 2020;41(39):3787–97. <https://doi.org/10.1093/eurheartj/ehaa455>. (Erratum in: *Eur Heart J*. 2021 Feb 11;42(6):680. PMID: 32840318; PMCID: PMC7846090).
  71. Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. *J Am Coll Cardiol*. 2014;64(15):1629–36. <https://doi.org/10.1016/j.jacc.2014.07.961>.
  72. van Hagen IM, Roos-Hesselink JW. Pregnancy in congenital heart disease: risk prediction and counselling. *Heart*. 2020;106(23):1853–61. <https://doi.org/10.1136/heartjnl-2019-314702>. (Epub 2020 Jul 1. PMID: 32611675; PMCID: PMC7677481).
  73. Almeida-Morais L, Pereira-da-Silva T, Branco L, Timóteo AT, Agapito A, de Sousa L, Oliveira JA, Thomas B, Jalles-Tavares N, Soares R, Galrinho A, Cruz-Ferreira R. The value of right ventricular longitudinal strain in the evaluation of adult patients with repaired tetralogy of Fallot: a new tool for a contemporary challenge. *Cardiol Young*. 2017;27(3):498–506. <https://doi.org/10.1017/S1047951116000810>.
  74. Veldtman GR, Connolly HM, Grogan M, Ammash NM, Warnes CA. Outcomes of pregnancy in women with tetralogy of Fallot. *J Am Coll Cardiol*. 2004;44(1):174–80. <https://doi.org/10.1016/j.jacc.2003.11.067>. (PMID: 15234429).



75. Cataldo S, Doohan M, Rice K, Trinder J, Stuart AG, Curtis SL. Pregnancy following Mustard or Senning correction of transposition of the great arteries: a retrospective study. *BJOG*. 2016;123(5):807–13. <https://doi.org/10.1111/1471-0528.13508>. (Epub 2015 Jul 3 PMID: 26138245).
76. Cauldwell M, Steer PJ, Bonner S, Asghar O, Swan L, Hodson K, Head CEG, Jakes AD, Walker N, Simpson M, Bolger AP, Siddiqui F, English KM, Maudlin L, Abraham D, Sands AJ, Mohan AR, Curtis SL, Coats L, Johnson MR. Retrospective UK multicentre study of the pregnancy outcomes of women with a Fontan repair. *Heart*. 2018;104(5):401–6. <https://doi.org/10.1136/heartjnl-2017-311763>. (Epub 2017 Sep 27 PMID: 28954835).
77. Davis MB, Arany Z, McNamara DM, Golland S, Elkayam U. Peripartum cardiomyopathy: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020;75(2):207–21. <https://doi.org/10.1016/j.jacc.2019.11.014>. (PMID: 31948651).

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

